-
Je něco špatně v tomto záznamu ?
Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition
K. Horackova, M. Janatova, P. Kleiblova, Z. Kleibl, J. Soukupova
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
NU20-03-00016
Ministry of Health
NU20-09-00355
Ministry of Health
NU23-03-00150
Ministry of Health
RVO-VFN 00064165
Ministry of Health
COOPERATIO
Charles University
SVV260516
Charles University
LX22NPO05102
Ministry of Education Youth and Sports
NLK
Free Medical Journals
od 2000
Freely Accessible Science Journals
od 2000
PubMed Central
od 2007
Europe PubMed Central
od 2007
ProQuest Central
od 2000-03-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2007-01-01
Health & Medicine (ProQuest)
od 2000-03-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
PubMed
38069345
DOI
10.3390/ijms242317020
Knihovny.cz E-zdroje
- MeSH
- dospělí MeSH
- epiteliální ovariální karcinom genetika MeSH
- genetická predispozice k nemoci * MeSH
- geny BRCA2 MeSH
- lidé MeSH
- nádory vaječníků * patologie MeSH
- protein BRCA1 genetika MeSH
- protein BRCA2 genetika MeSH
- rizikové faktory MeSH
- zárodečné mutace MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Ovarian cancer (OC) is one of the leading causes of cancer-related deaths in women. Most patients are diagnosed with advanced epithelial OC in their late 60s, and early-onset adult OC diagnosed ≤30 years is rare, accounting for less than 5% of all OC cases. The most significant risk factor for OC development are germline pathogenic/likely pathogenic variants (GPVs) in OC predisposition genes (including BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, Lynch syndrome genes, or BRIP1), which contribute to the development of over 20% of all OC cases. GPVs in BRCA1/BRCA2 are the most prevalent. The presence of a GPV directs tailored cancer risk-reducing strategies for OC patients and their relatives. Identification of OC patients with GPVs can also have therapeutic consequences. Despite the general assumption that early cancer onset indicates higher involvement of hereditary cancer predisposition, the presence of GPVs in early-onset OC is rare (<10% of patients), and their heritability is uncertain. This review summarizes the current knowledge on the genetic predisposition to early-onset OC, with a special focus on epithelial OC, and suggests other alternative genetic factors (digenic, oligogenic, polygenic heritability, genetic mosaicism, imprinting, etc.) that may influence the development of early-onset OC in adult women lacking GPVs in known OC predisposition genes.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000572
- 003
- CZ-PrNML
- 005
- 20240213093252.0
- 007
- ta
- 008
- 240109s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/ijms242317020 $2 doi
- 035 __
- $a (PubMed)38069345
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Horackova, Klara $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000273904751
- 245 10
- $a Early-Onset Ovarian Cancer <30 Years: What Do We Know about Its Genetic Predisposition / $c K. Horackova, M. Janatova, P. Kleiblova, Z. Kleibl, J. Soukupova
- 520 9_
- $a Ovarian cancer (OC) is one of the leading causes of cancer-related deaths in women. Most patients are diagnosed with advanced epithelial OC in their late 60s, and early-onset adult OC diagnosed ≤30 years is rare, accounting for less than 5% of all OC cases. The most significant risk factor for OC development are germline pathogenic/likely pathogenic variants (GPVs) in OC predisposition genes (including BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, Lynch syndrome genes, or BRIP1), which contribute to the development of over 20% of all OC cases. GPVs in BRCA1/BRCA2 are the most prevalent. The presence of a GPV directs tailored cancer risk-reducing strategies for OC patients and their relatives. Identification of OC patients with GPVs can also have therapeutic consequences. Despite the general assumption that early cancer onset indicates higher involvement of hereditary cancer predisposition, the presence of GPVs in early-onset OC is rare (<10% of patients), and their heritability is uncertain. This review summarizes the current knowledge on the genetic predisposition to early-onset OC, with a special focus on epithelial OC, and suggests other alternative genetic factors (digenic, oligogenic, polygenic heritability, genetic mosaicism, imprinting, etc.) that may influence the development of early-onset OC in adult women lacking GPVs in known OC predisposition genes.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a genetická predispozice k nemoci $7 D020022
- 650 _2
- $a protein BRCA2 $x genetika $7 D024682
- 650 _2
- $a protein BRCA1 $x genetika $7 D019313
- 650 _2
- $a geny BRCA2 $7 D024522
- 650 12
- $a nádory vaječníků $x patologie $7 D010051
- 650 _2
- $a epiteliální ovariální karcinom $x genetika $7 D000077216
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a zárodečné mutace $7 D018095
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Janatova, Marketa $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000328166769
- 700 1_
- $a Kleiblova, Petra $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000248069854 $7 xx0125463
- 700 1_
- $a Kleibl, Zdenek $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000320509667 $7 jo2003183974
- 700 1_
- $a Soukupova, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000324131542 $7 xx0239539
- 773 0_
- $w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 24, č. 23 (2023)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38069345 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093249 $b ABA008
- 999 __
- $a ok $b bmc $g 2049313 $s 1210266
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 24 $c 23 $e 20231130 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
- GRA __
- $a NU20-03-00016 $p Ministry of Health
- GRA __
- $a NU20-09-00355 $p Ministry of Health
- GRA __
- $a NU23-03-00150 $p Ministry of Health
- GRA __
- $a RVO-VFN 00064165 $p Ministry of Health
- GRA __
- $a COOPERATIO $p Charles University
- GRA __
- $a SVV260516 $p Charles University
- GRA __
- $a LX22NPO05102 $p Ministry of Education Youth and Sports
- LZP __
- $a Pubmed-20240109